Relevant bibliographies by topics / Neurosarcoidosis

Academic literature on the topic 'Neurosarcoidosis'

Author: Grafiati
Published: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Neurosarcoidosis.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Neurosarcoidosis"

1

Lord, Jennifer, M. Mateo Paz Soldan, Jonathan Galli, Karen L. Salzman, Jacob Kresser, Rae Bacharach, L. Dana DeWitt, et al. "Neurosarcoidosis." Neurology - Neuroimmunology Neuroinflammation 7, no. 4 (May 13, 2020): e743. http://dx.doi.org/10.1212/nxi.0000000000000743.

Full text
Abstract:
ObjectiveTo characterize patients with neurosarcoidosis within the University of Utah healthcare system, including demographics, clinical characteristics, treatment, and long-term outcomes.MethodsWe describe the clinical features and outcomes of patients with neurosarcoidosis within the University of Utah healthcare system (a large referral center for 10% of the continental United States by land mass). Patients were selected who met the following criteria: (1) at least one International Classification of Diseases Clinical Modification, 9th revision code 135 or International Classification of Diseases Clinical Modification, 10th revision code D86* (sarcoidosis) and (2) at least one outpatient visit with a University of Utah clinician in the Neurology Department within the University of Utah electronic health record.ResultsWe identified 56 patients meeting the study criteria. Thirty-five patients (63%) were women, and most patients (84%) were white. Twelve patients (22%) met the criteria for definite neurosarcoidosis, 36 patients (64%) were diagnosed with probable neurosarcoidosis, and 8 patients (14%) were diagnosed with possible neurosarcoidosis. A total of 8 medications were used for the treatment of neurosarcoidosis. Prednisone was the first-line treatment in 51 patients (91%). Infliximab was the most effective therapy, with 87% of patients remaining stable or improving on infliximab. Treatment response for methotrexate and azathioprine was mixed, and mycophenolate mofetil and rituximab were the least effective treatments in this cohort.ConclusionsThis is a comprehensive characterization of neurosarcoidosis within a single healthcare system at the University of Utah that reports long-term response to treatment and outcomes of patients with neurosarcoidosis. Our results suggest the use of infliximab as a first-line therapy for neurosarcoidosis.
APA, Harvard, Vancouver, ISO, and other styles
2

Tetikkurt, Cuneyt. "Neurosarcoidosis." Journal of Neurology & Neuromedicine 3, no. 4 (July 1, 2018): 108–12. http://dx.doi.org/10.29245/2572.942x/2018/4.1190.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Brola, Waldemar, Renata Pejas-Dulewicz, Jarosław Wasiński, and Małgorzata Fudala. "Neurosarcoidosis." Medical Studies 1 (2014): 51–56. http://dx.doi.org/10.5114/ms.2014.42002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ramazanov, G. R., E. V. Shevchenko, L. I. Idilova, V. N. Stepanov, E. V. Nugaeva, and S. S. Petrikov. "Neurosarcoidosis." Russian neurological journal 25, no. 5 (December 16, 2020): 45–50. http://dx.doi.org/10.30629/2658-7947-2020-25-5-45-50.

Full text
Abstract:
The article represents the discussion of sarcoidosis involving the cranial nerves and meninges. It’s a rare disease difficult to diagnose. This form of the disease is a progressive lesion of the nervous system, characterized by granulomatous inflammation of the membranes and /or tissue of cerebrum or spinal cord, cranial and /or peripheral nerves. Clinical signs of the nervous system disorder found in sarcoidosis, are detected only in 5–15% of patients. They are often represented by symptoms of cranial nerve damage, meningeal syndrome and epileptic seizures. X-ray computed tomography and magnetic resonance imaging of the brain do not reveal specific changes, however, they allow to exclude other structural lesions of the central nervous system and to identify neuroimaging signs, most common in the course of this disease. Diagnosis of neurosarcoidosis is possible in the presence of neurological symptoms, signs of multisystem lesions, and histological confirmation of non-caseous granulomatous inflammation in one or more organs. The article also represents a clinical observation of a patient with neurosarcoidosis, manifested by acute bilateral neuropathy of the facial nerves, unilateral neuropathy of the trigeminal nerve and meningism syndrome. The neuroimaging signs, often found in this disease, were revealed: the accumulation of contrast agent by the membranes of the brain and the tissue of cavum Meckeli. The course of the disease and diagnostic search, which made it possible to detect signs of multisystem lesion, are described. The diagnosis was confirmed by histological examination of the biopsy material of the intrathoracic lymph node. The results of neurosarcoidosis anti-inflammatory therapy are presented. The peculiarities influencing the choice of this type of treatment terms, are indicated.
APA, Harvard, Vancouver, ISO, and other styles
5

Lacomis, David. "Neurosarcoidosis." Current Neuropharmacology 9, no. 3 (September 1, 2011): 429–36. http://dx.doi.org/10.2174/157015911796557975.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bradshaw, Michael J., Siddharama Pawate, Laura L. Koth, Tracey A. Cho, and Jeffrey M. Gelfand. "Neurosarcoidosis." Neurology - Neuroimmunology Neuroinflammation 8, no. 6 (October 4, 2021): e1084. http://dx.doi.org/10.1212/nxi.0000000000001084.

Full text
Abstract:
Although often regarded as a protean illness with myriad clinical and imaging manifestations, neurosarcoidosis typically presents as recognizable syndromes that can be approached in a rational, systematic fashion. Understanding of neurosarcoidosis has progressed significantly in recent years, including updated diagnostic criteria and advances in treatment. The diagnosis of neurosarcoidosis is established by the clinical syndrome, imaging and histopathological findings, and exclusion of other causes. Mounting evidence supports the use of tumor necrosis factor inhibitors as an important addition to the therapeutic armamentarium, along with glucocorticoids and steroid-sparing cytotoxic immunosuppressants. In this narrative review, we summarize recent advances in the diagnosis and treatment of neurosarcoidosis.
APA, Harvard, Vancouver, ISO, and other styles
7

Williams, Daniel W., Allen D. Elster, and Stephen I. Kramer. "Neurosarcoidosis." Journal of Computer Assisted Tomography 14, no. 5 (September 1990): 704–7. http://dx.doi.org/10.1097/00004728-199009000-00004.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Minagar, A., M. Hardjasudarma, and R. E. Kelley. "Neurosarcoidosis." Neurology 59, no. 3 (August 13, 2002): 477. http://dx.doi.org/10.1212/wnl.59.3.477.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Oksanen, Virpi. "Neurosarcoidosis." Seminars in Respiratory and Critical Care Medicine 13, no. 06 (November 1992): 459–67. http://dx.doi.org/10.1055/s-2007-1006296.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Schooff, Michael. "NEUROSARCOIDOSIS." Southern Medical Journal 86, Supplement (September 1993): 35. http://dx.doi.org/10.1097/00007611-199309001-00089.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Neurosarcoidosis"

1

GRAGNOLINI, PASCAL. "La neurosarcoidose : a propos de huit observations." Clermont-Ferrand 1, 1990. http://www.theses.fr/1990CLF13031.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bocci, Silvia. "Clinico-pathological variability and proposal of new biomarkers in central nervous system and muscular sarcoidosis." Doctoral thesis, 2022. http://hdl.handle.net/2158/1277999.

Full text
Abstract:
Sarcoidosis is a multi-system granulomatous disease of unknown etiology characterized by the infiltration of various organs by non-necrotizing granulomas. Disease morbidity is strictly related to the mechanisms that govern granulomatous inflammation, including the release of pro-inflammatory cytokines (mainly IFNγ, IL-2 and TNFα) by immune cells. An important and debated role in sarcoidosis diagnosis is played by serum biomarkers such as angiotensin-converting enzyme (ACE), lysozyme (LSZ), chitotriosidase (CTO) and Krebs von den lungen-6 (KL-6). Neurosarcoidosis is namely the involvement of central and/or peripheral nervous system by sarcoid granulomas. Symptomatic nervous system involvement is reported in 3-16% of patients with sarcoidosis, but post-mortem studies report higher prevalence. Moreover, neurosarcoidosis can present isolated (with no other organ involvement) in about 10% of cases and neurologic manifestations can be the presenting syndrome of sarcoidosis in more than 50% of cases. Finally, neurosarcoidosis can virtually involve every part of CNS and PNS or skeletal muscle with polymorphic clinical presentations. Three main sets of diagnostic criteria have been proposed in the literature to define neurosarcoidosis, all attributing the highest grade of diagnostic certainty to cases with CNS or PNS/muscle pathology demonstrating sarcoid granulomas. Moreover, brain and spinal cord MRI and cerebrospinal fluid (CSF) analysis are the main diagnostic tools taken into account by the aforementioned criteria, but the specificity of their finding is often poor. Therefore, CNS and neuromuscular presentations of sarcoidosis represent a diagnostic challenge for neurologists. Thanks to the cooperation with the Sarcoidosis Regional Referral Center, managed by Respiratory Diseases and Lung Transplantation Unit of the University Hospital of Siena, we were able to evaluate and follow a large number of sarcoidosis patients with suspected or confirmed neurologic involvement. Therefore, we decided to critically analyze the data derived from consultant activity and to perform focused clinico-pathologic studies, in order to gain more insight on the disease and its complications, and to propose new diagnostic tools. Specifically, our study was developed in three main parts: (i) A retrospective cohort study on a population of CNS neurosarcoidosis patients, performed with the aims of identifying recurrent or peculiar clinical patterns and evaluating the possible use of established diagnostic criteria in clinical practice; (ii) A controlled study on serum and CSF biomarkers of CNS neurosarcoidosis including KL-6 (a mucin-like glycoprotein secreted by type II pneumocytes, increased in serum and BAL of patients with ILD and sarcoidosis), which was never systematically investigated in this localization of the disease; (iii) A retrospective/prospective cohort study on sarcoidosis patients undergoing muscular biopsy, in order to define every clinico-pathological presentation and investigate, for the first time, the role of TNFα in sarcoid myopathy. (i). From the retrospective review of the charts from Sarcoidosis Regional Referral Center we identified 22 patients who fulfilled criteria for possible neurosarcoidosis or higher in at least one of the proposed diagnostic criteria. Neurologic symptoms were the presenting feature of sarcoidosis in 59,1% of patients and pathological confirmation of sarcoidosis was available in 17 of them (in one patient it was obtained in CNS biopsy, allowing diagnosis of defined neurosarcoidosis). Lesions involved brain parenchyma, meninges, spinal cord, cranial nerves, hypothalamus/hypophysis and intracranial arteries, and 8 patients had multiple localizations. Most useful investigations for the diagnosis were MRI (positive in 20 patients and showing post-contrast enhancement in 16) and CSF analysis (showing inflammatory findings in 11 out of 13 patients), while classic serum biomarkers such as ACE and lysozyme were increased only in a small proportion of patients; instead, serum chitotriosidase (CTO) was significantly increased in the majority of the tested patients. (ii). From this cohort, we retrospectively enrolled patients for whom samples of serum and CSF had been simultaneously collected and stored at -20°C and were available for further analysis. We enrolled 9 patients with a chronic inflammatory disease, namely multiple sclerosis (MS), and 9 patients with a chronic neurodegenerative disease, namely amyotrophic lateral sclerosis (ALS), as control groups. Serum samples from 9 healthy controls were also collected for KL-6 assay. The four groups were matched for sex and age. Measurable CSF concentrations of KL-6 were detected in 7/9 NS patients but in no ALS or MS patients. In NS patients, CSF concentrations of KL-6 were directly correlated with CSF albumin index, albumin, IgG and total protein concentrations. As KL-6 is a high molecular weight (200 kDa) protein produced outside the central nervous system, it is unable to diffuse in CSF when blood-brain barrier is intact. Instead, when the barrier is damaged as in NS, KL-6 could cross it. This interpretation is confirmed by the direct correlation between KL-6 concentration in CSF and albumin index. Our finding of KL-6 in CSF of NS patients but not in ALS and MS patients suggests that this protein may discriminate this specific phenotype of sarcoidosis with 81,2% sensitivity and 100% specificity. (iii). Regarding skeletal muscle involvement, we performed a retrospective/prospective cohort study, enrolling 29 sarcoidosis patient who underwent muscular biopsy due to suspect muscular involvement. General myopathic changes, with different degrees of inflammation, were detected in almost all patients, while granulomas were detected only in 4/29 patients. Inflammatory changes ranged from massive endomysial infiltrates to minimal perivasal deposits. Upregulation of tissue immunity markers was observed. Electron microscopy confirmed endothelial involvement in most cases. Associated neurogenic changes were also detected in a subgroup. Our findings support the hypothesis of symptomatic muscle involvement in sarcoidosis besides granulomatous sarcoid myositis. Local and circulating cytokines result crucial in Th1 inflammatory response of sarcoidosis and increased circulating TNFα is considered a possible cause of sarcoidosis associated small fiber neuropathy. Therefore, in order to investigate the pathophysiology of non-granulomatous sarcoid related myositic changes and of the common muscle pain complaint in these patients, we investigated by immunocytochemical localization tissue expression of TNFα and its receptors (TNFR1-2) in 9 patients from our cohort and in healthy controls. An endothelial increase and sarcolemmal/sarcoplasmic deposition of TNFα/TNFR1-2 was detected in all cases, with or without granulomas, including samples with minimal pathological or immunohistologic changes. Our findings suggest that TNFα/TNFR1-2 may represent a sensitive diagnostic marker, especially in milder presentations of sarcoid myopathy, and underline the relevance of capillary endothelium as the first site of the pathological process.
APA, Harvard, Vancouver, ISO, and other styles
3

Cavaco, Sónia Isabel Pires. "Caso clínico : neurosarcoidose com envolvimento neuroftalmológico." Master's thesis, 2014. http://hdl.handle.net/10451/24571.

Full text
Abstract:
Trabalho Final do Curso de Mestrado Integrado em Medicina, Faculdade de Medicina, Universidade de Lisboa, 2014
Introduction: Sarcoidosis is a multisystem disorder of unknown origin, whose histological hallmark is the presence of noncaseating granulomas. When sarcoidosis lesions affect the optic nerve, we are in the presence of neurosarcoidosis with neuro-ophtalmological involvement. The diagnosis and treatment is a challenge, and the prognosis is highly variable, from spontaneous remission to chronic and progres-sive disease. Purpose: To describe the evolution of a case, from the moment that the first complaints arise, to the present day – for five years, focusing on diagnosis and treatment, as well as the adverse effects associ-ated with the drugs. Case report: 36 year old female patient, with recurrent complaints of headache and bilateral decreased vision, with 4 months of evolution. Cranial nuclear magnetic resonance revealed a contrast-enhanced lesion adjacent to the optic chiasm. Corticosteroid therapy was initiated, with subjective improvement of vision. Because the patient was corticodependent, a biopsy of the right optic nerve was performed, which revealed neurosarcoidosis. Patient developed several comorbidities as a consequence of cortico-therapy, so other immunosuppressive drugs have been used, methotrexate to which the patient is refrac-tory; and subsequently infliximab, obtaining stability of visual function. Conclusions: When only the nervous system is affected, it’s very difficult to obtain a definite diagno-sis, taking into account the risk/benefit of biopsies in these cases. In the presence of a definite diagnosis, still remains the question of therapy, and sometimes is necessary to use medication with numerous adverse effects in order to stabilize the patient.
Introdução: A sarcoidose é uma doença multissistémica, de etiologia desconhecida, cuja marca histo-lógica é a presença de granulomas não caseosos. Quando as lesões da sarcoidose afetam o nervo óptico, estamos na presença de neurosarcoidose com envolvimento neuroftalmológico. O diagnóstico e o tratamento constituem um desafio, e o prognóstico é muito variável, desde remissão espontânea até doen-ça crónica e progressiva. Objetivo: Descrever a evolução de um caso clínico, desde o momento em que surgem as primeiras queixas, até à atualidade – durante 5 anos, com foco no diagnóstico e no tratamento, bem como nos efeitos adversos associados aos fármacos utilizados. Caso Clínico: Doente do sexo feminino, 36 anos, com queixas recorrentes de cefaleias e diminuição da acuidade visual (AV) bilateral com 4 meses de evolução. A ressonância magnética nuclear (RMN ) crâ-nio-encefálica (CE) revelou lesão com captação de contraste, adjacente ao quiasma. Foi iniciada corticoterapia, com melhoria subjetiva da AV. Por ser corticodependente, foi realizada biopsia ao nervo óp-tico direito, que revelou neurosarcoidose. Uma vez que desenvolveu diversas comorbilidades, como consequência da corticoterapia, foram utilizados outros fármacos imunossupressores, o metotrexato, ao qual a doente é refratária e, posteriormente, o infliximab, obtendo-se estabilidade da função visual. Conclusões: O diagnóstico definitivo nos casos em que apenas é afetado o sistema nervoso é muito difícil de se obter, tendo em conta o risco/benefício das biopsias nesses casos. Perante um diagnóstico definitivo, ainda se mantém a questão da terapêutica, sendo por vezes necessário utilizar medicação com inúmeros efeitos adversos de forma a estabilizar o doente.
APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Neurosarcoidosis"

1

Miller, Aaron E., and Teresa M. DeAngelis. Neurosarcoidosis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199732920.003.0015.

Full text
Abstract:
Sarcoidosis is a multi-systemic, inflammatory, granulomatous disorder of unknown etiology, characterized pathologically by the presence of noncaseating granulomas and multinucleated giant cells. Involvement of the nervous system is estimated in 5% of patients with systemic sarcoidosis, and rarely occurs as an isolated phenomenon. In this chapter, we review the most common peripheral and central presentations of neurosarcoidosis.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Neurosarcoidosis"

1

Scott, Thomas F. "Neurosarcoidosis." In Multiple Sclerosis and CNS Inflammatory Disorders, 163–68. Chichester, UK: John Wiley & Sons, Ltd., 2014. http://dx.doi.org/10.1002/9781118298633.ch16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Bradshaw, Michael J., Siddharama Pawate, and Jeffrey A. Sparks. "Neurosarcoidosis." In Neurorheumatology, 73–85. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-16928-2_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

van Staalduinen, Eric. "Neurosarcoidosis." In PET/MR Imaging, 329–30. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-65106-4_133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gullapalli, Dakshinamurty, and Lawrence H. Phillips. "Neurosarcoidosis." In Inflammatory Disorders of the Nervous System, 269–90. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1385/1-59259-905-2:269.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Eaton, James E., and Siddharama Pawate. "Neurosarcoidosis." In Neuroimmunology, 373–84. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-61883-4_23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Aachi, Ragav, Marjorie Fowler, Eduardo Gonzalez-Toledo, Jeanie McGee, and Alireza Minagar. "Neurosarcoidosis: Clinical Features, Pathogenesis, and Management." In Inflammatory Disorders of the Nervous System, 121–37. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51220-4_5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mineura, K., T. Sasajima, M. Kowada, T. Ogawa, J. Hatazawa, and K. Uemura. "Positron emission tomography in the differential diagnosis of neurosarcoidosis and cerebral gliomas." In Proceedings of the XV Symposium Neuroradiologicum, 161–63. Berlin, Heidelberg: Springer Berlin Heidelberg, 1995. http://dx.doi.org/10.1007/978-3-642-79434-6_78.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Grzybowski, Andrzej, Francisco J. Ascaso, Javier Mateo, Laura Cabezón, and Paula Casas. "Other Neurological Disorders: Migraine, Neurosarcoidosis, Schizophrenia, Obstructive Sleep Apnea-Hypopnea Syndrome (OSAHS)." In OCT in Central Nervous System Diseases, 167–83. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-24085-5_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ascaso, Francisco J., Javier Mateo, Laura Cabezón, Paula Casas, and Andrzej Grzybowski. "Other Neurological Disorders: Migraine, Neurosarcoidosis, Schizophrenia, Obstructive Sleep Apnea-Hypopnea Syndrome and Bipolar Disorder." In OCT and Imaging in Central Nervous System Diseases, 317–42. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-26269-3_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stern, Barney J. "Neurosarcoidosis." In Office Practice of Neurology, 1221–24. Elsevier, 2003. http://dx.doi.org/10.1016/b0-44-306557-8/50193-3.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Neurosarcoidosis"

1

Barath, Stefan. "Diagnosing Neurosarcoidosis With EBUS-TBNA." In American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a5824.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Sawal, N., and G. Johri. "Neurosarcoidosis Induced Longitudinally Extensive Transverse Myelitis." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3291.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Moraes, Patrícia Milani de, Taísa Morete da Silva, Carlos Augusto Rodrigues Padilha, Maria Juliana da Silva Almeida, Bruna Lordão Alves, Ana Clara Bertelli Roseiro, Lucas Alves Oltramari, and Renata Vaz de Oliveira. "MEDULLARY EPICONUS SYNDROME DUE TO NEUROSARCOIDOSIS." In XXXIX Congresso Brasileiro de Reumatologia. Sociedade Brasileiro de Reumatologia, 2022. http://dx.doi.org/10.47660/cbr.2022.1933.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Fuller, Brittany S., and Lobelia Samavati. "Neurosarcoidosis And The Value Of Pulmonary Evaluation." In American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Setty, Sabitha S., and Alvin S. Teirstein. "Neurosarcoidosis Presenting As Bilateral Vocal Cord Paralysis." In American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5404.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tauscher, S. "Neurosarcoidosis, Not an Easy Diagnosis to Ace." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4067.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Kempisty, Anna, Katarzyna Blasinska-Przerwa, Elzbieta Marcinkowska, and Jan Kus. "Neurological signs in patients with sarcoidosis - is it neurosarcoidosis?" In ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa3264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Case, R., H. M. Alnuaimat, D. C. Gomez Manjarres, and D. C. Patel. "Development of Neurosarcoidosis Following Bilateral Lung Transplantation for Sarcoidosis." In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Hendrickson, J. F., and R. P. Nayak. "Delayed Diagnosis of Sarcoidosis Leading to Unintended Progression of Neurosarcoidosis." In American Thoracic Society 2022 International Conference, May 13-18, 2022 - San Francisco, CA. American Thoracic Society, 2022. http://dx.doi.org/10.1164/ajrccm-conference.2022.205.1_meetingabstracts.a4073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Fontes-Villalba, Ariadna, Dayna Griffiths, Natasha Gerbis, Jonathan Baird-Gunning, Patrick Aouad, Suran Fernando, and John Parratt. "108 The diagnosis and management of five cases of spinal neurosarcoidosis." In ANZAN Annual Scientific Meeting 2021 Abstracts. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/bmjno-2021-anzan.108.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Neurosarcoidosis' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography